Regeneron Pharmaceuticals Inc. and Sanofi won U.S. Food and Drug Administration approval for their first immuno-oncology drug, a therapy that the companies hope will jump-start their cancer joint venture.
Libtayo, also known as cemiplimab, treats a deadly form of skin cancer. It’s the first drug to come out of the companies’ 2015 partnership to research therapies that use the body’s immune system to fight various malignancies. Since the companies struck their deal, Merck & Co.’s blockbuster cancer treatment, Keytruda, has edged out rivals to become the dominant product among a new class of cancer drugs.
Despite the competitive landscape, the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.